Glufast On Insulin Glargine Trial in Type 2 DM

Exclusion Criteria

• •The patients who have been using insulin formulation except insulin glargine
• •The patients whose fasting blood glucose is over 270 mg/dL
• •The patients whose C-peptide is under 1ng/ml on an empty stomach
• •The patients who was surgically operated of gastrointestinal tract
• •The patients who need additional treatment or who underwent operation within 3 months for severe complication such as diabetic foot ulcer, retinopathy and neuropathy
• •The patients with severe hepatic dysfunction : uncompensated hepatic cirrhosis, or the case where aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is over 2.5 times higher than the normal limit ( ≥ 2.5 x normal ranges)
• •The patients with unstable angina or acute myocardial infarction occurred within 3months
• •The patients with renal failure or severe hypertension : diastolic blood pressure is over 110mmHg despite drug treatment
• •The patients who have a life-threatening disease such as cancer or severe infection
• •The patients with a history of drug allergy
• •Pregnant or breast feeding or the women who are likely to be pregnant
• •The patients who need oral or parenteral corticosteroids
• •The patients who were judged to be unsuitable to the clinical study by other reasons